Integrated profiling of MicroRNAs and mRNAs: MicroRNAs Located on Xq27.3 associate with clear cell renal cell carcinoma

PLoS ONE

Volumn 5, Issue 12, 2010, Pages

  Zhou, Liang ^a   Chen, Jiahao ^b,c   Li, Zhizhong ^b,c   Li, Xianxin ^a   Hu, Xueda ^b,d,e   Huang, Yi ^a   Zhao, Xiaokun ^f   Liang, Chaozhao ^g   Wang, Yong ^a   Sun, Liang ^a   Shi, Min ^a   Xu, Xiaohong ^b   Shen, Feng ^b   Chen, Maoshan ^b   Han, Zujing ^b   Peng, Zhiyu ^b   Zhai, Qingna ^a   Chen, Jing ^a   Zhang, Zhongfu ^a   Yang, Ruilin ^a,h   Ye, Jiongxian ^a   Guan, Zhichen ^a   Yang, Huanming ^b   Gui, Yaoting ^a   Wang, Jun ^b   Cai, Zhiming ^a   Zhang, Xiuqing ^b   more..

^a Biomedical Research Institute   (China)

^b BGI SHENZHEN   (China)

^c SOUTH CHINA UNIVERSITY OF TECHNOLOGY   (China)

^d Chinese Academy of Sciences and China National Center for Bioinformation   (China)

^e UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^f CENTRAL SOUTH UNIVERSITY   (China)

^g ANHUI MEDICAL UNIVERSITY   (China)

^h SHANTOU UNIVERSITY MEDICAL COLLEGE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DUAL SPECIFICITY PHOSPHATASE 9; EPIDERMAL GROWTH FACTOR RECEPTOR 4; MESSENGER RNA; MICRORNA; MICRORNA 122; MICRORNA 184; MICRORNA 206; MICRORNA 210; PHOSPHATASE; RNA; UNCLASSIFIED DRUG; VASCULOTROPIN A;

ARTICLE; CARCINOGENESIS; CELL FATE; CHROMOSOME XQ; CLEAR CELL CARCINOMA; CONTROLLED STUDY; DOWN REGULATION; GENE CLUSTER; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE LOCATION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY CARCINOMA; PHENOTYPE; REAL TIME POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; UPREGULATION; VALIDATION PROCESS; APOPTOSIS; BIOLOGICAL MODEL; CELL CYCLE; GENETICS; KIDNEY TUMOR; METABOLISM; METASTASIS; METHODOLOGY; REPRODUCIBILITY; STATISTICAL MODEL; X CHROMOSOME;

APOPTOSIS; CARCINOMA, RENAL CELL; CELL CYCLE; CHROMOSOMES, HUMAN, X; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KIDNEY NEOPLASMS; MICRORNAS; MODELS, GENETIC; MODELS, STATISTICAL; NEOPLASM METASTASIS; PHENOTYPE; REPRODUCIBILITY OF RESULTS; RNA, MESSENGER;

EID: 78651253572     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0015224     Document Type: Article

References (68)

1. Lopez-Beltran A, Carrasco JC, Cheng L, Scarpelli M, Kirkali Z, et al. (2009) 2009 update on the classification of renal epithelial tumors in adults. Int J Urol 16: 432-443.
2. Seifert G, Brocheriou C, Cardesa A, Eveson JW (1990) WHO International Histological Classification of Tumours. Tentative Histological Classification of Salivary Gland Tumours. Pathol Res Pract 186: 555-581.
3. Rini B, Campbell S, Escudier B (2009) Renal cell carcinoma. The Lancet 373: 1119-1132.
4. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA: A Cancer Journal for Clinicians. 60: 277-300.
5. Parkin D, Pisani P, Lopez A, Masuyer E (1994) At least one in seven cases of cancer is caused by smoking. Global estimates for 1985. International journal of cancer 59: 494-504.
6. Cohen H, McGovern F (2005) Renal-cell carcinoma. New England Journal of Medicine 353: 2477.
7. Gnarra JR, Tory K, Weng Y, Schmidt L, Wei MH, et al. (1994) Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 7: 85-90.
8. Maranchie JK, Vasselli JR, Riss J, Bonifacino JS, Linehan WM, et al. (2002) The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell 1: 247-255.
9. Smith K, Gunaratnam L, Morley M, Franovic A, Mekhail K, et al. (2005) Silencing of epidermal growth factor receptor suppresses hypoxia-inducible factor-2-driven VHL-/- renal cancer. Cancer Res 65: 5221-5230.
10. Huang Y, Dai Y, Yang J, Chen T, Yin Y, et al. (2009) Microarray analysis of microRNA expression in renal clear cell carcinoma. Eur J Surg Oncol 35: 1119-1123.
11. Kosari F, Parker AS, Kube DM, Lohse CM, Leibovich BC, et al. (2005) Clear cell renal cell carcinoma: gene expression analyses identify a potential signature for tumor aggressiveness. Clin Cancer Res 11: 5128-5139.
12. Jung M, Mollenkopf HJ, Grimm C, Wagner I, Albrecht M, et al. (2009) MicroRNA profiling of clear cell renal cell cancer identifies a robust signature to define renal malignancy. J Cell Mol Med 13: 3918-3928.
13. Garzon R, Calin GA, Croce CM (2009) MicroRNAs in Cancer. Annu Rev Med 60: 167-179.
14. Kim VN (2005) MicroRNA biogenesis: coordinated cropping and dicing. Nat Rev Mol Cell Biol 6: 376-385.
15. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, et al. (2005) MicroRNA expression profiles classify human cancers. Nature 435: 834-838.
16. Gottardo F, Liu CG, Ferracin M, Calin GA, Fassan M, et al. (2007) Micro-RNA profiling in kidney and bladder cancers. Urol Oncol 25: 387-392.
17. Chow TF, Youssef YM, Lianidou E, Romaschin AD, Honey RJ, et al. (2010) Differential expression profiling of microRNAs and their potential involvement in renal cell carcinoma pathogenesis. Clin Biochem 43: 150-158.
18. Liu H, Brannon AR, Reddy AK, Alexe G, Seiler MW, et al. (2010) Identifying mRNA targets of microRNA dysregulated in cancer: with application to clear cell Renal Cell Carcinoma. BMC Syst Biol 4: 51.
19. t Hoen P, Ariyurek Y, Thygesen H, Vreugdenhil E, Vossen R, et al. (2008) Deep sequencing-based expression analysis shows major advances in robustness, resolution and inter-lab portability over five microarray platforms. Nucleic acids research 36: e141.
20. Morrissy AS, Morin RD, Delaney A, Zeng T, McDonald H, et al. (2009) Nextgeneration tag sequencing for cancer gene expression profiling. Genome Res 19: 1825-1835.
21. Bernascone I, Janas S, Ikehata M, Trudu M, Corbelli A, et al. (2010) A transgenic mouse model for uromodulin-associated kidney diseases shows specific tubulo-interstitial damage, urinary concentrating defect and renal failure. Human molecular genetics 19: 2998-3010.
22. Verkman A (2000) Renal concentrating and diluting function in deficiency of specific aquaporin genes. Experimental nephrology 10: 235-240.
23. Torres AM (2008) Renal elimination of organic anions in cholestasis. World J Gastroenterol 14: 6616-6621.
24. Mizuno N, Takahashi T, Iwase Y, Kusuhara H, Niwa T, et al. (2007) Human organic anion transporters 1 (hOAT1/SLC22A6) and 3 (hOAT3/SLC22A8) transport edaravone (MCI-186; 3-methyl-1-phenyl-2-pyrazolin-5-one) and its sulfate conjugate. Drug Metab Dispos 35: 1429-1434.
25. Chen Y, Stallings RL (2007) Differential patterns of microRNA expression in neuroblastoma are correlated with prognosis, differentiation, and apoptosis. Cancer Res 67: 976-983.
26. Shan ZX, Lin QX, Deng CY, Zhu JN, Mai LP, et al. (2010) miR-1/miR-206 regulate Hsp60 expression contributing to glucose-mediated apoptosis in cardiomyocytes. FEBS Lett 584: 3592-3600.
27. Camps C, Buffa F, Colella S, Moore J, Sotiriou C, et al. (2008) hsa-miR-210 Is induced by hypoxia and is an independent prognostic factor in breast cancer. Clinical Cancer Research 14: 1340-1348.
28. Pulkkinen K, Malm T, Turunen M, Koistinaho J, Yla-Herttuala S (2008) Hypoxia induces microRNA miR-210 in vitro and in vivo ephrin-A3 and neuronal pentraxin 1 are potentially regulated by miR-210. FEBS Lett 582: 2397-2401.
29. Kutay H, Bai S, Datta J, Motiwala T, Pogribny I, et al. (2006) Downregulation of miR-122 in the rodent and human hepatocellular carcinomas. J Cell Biochem 99: 671-678.
30. Metzler M, Wilda M, Busch K, Viehmann S, Borkhardt A (2004) High expression of precursor microRNA-155/BIC RNA in children with Burkitt lymphoma. Genes Chromosomes Cancer 39: 167-169.
31. Kluiver J, Poppema S, de Jong D, Blokzijl T, Harms G, et al. (2005) BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas. J Pathol 207: 243-249.
32. Calin GA, Ferracin M, Cimmino A, Di Leva G, Shimizu M, et al. (2005) A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 353: 1793-1801.
33. Garzon R, Volinia S, Liu CG, Fernandez-Cymering C, Palumbo T, et al. (2008) MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood 111: 3183-3189.
34. Zhang L, Huang J, Yang N, Greshock J, Megraw MS, et al. (2006) microRNAs exhibit high frequency genomic alterations in human cancer. Proc Natl Acad Sci U S A 103: 9136-9141.
35. Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, et al. (2006) Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 9: 189-198.
36. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, et al. (2006) A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A 103: 2257-2261.
37. Hurteau GJ, Carlson JA, Spivack SD, Brock GJ (2007) Overexpression of the microRNA hsa-miR-200c leads to reduced expression of transcription factor 8 and increased expression of E-cadherin. Cancer Res 67: 7972-7976.
38. Park SM, Gaur AB, Lengyel E, Peter ME (2008) The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev 22: 894-907.
39. Korpal M, Lee ES, Hu G, Kang Y (2008) The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem 283: 14910-14914.
40. Kanehisa M, Goto S (2000) KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res 28: 27-30.
41. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, et al. (2003) Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 13: 2498-2504.
42. Bindea G, Mlecnik B, Hackl H, Charoentong P, Tosolini M, et al. (2009) ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. Bioinformatics 25: 1091-1093.
43. Tun HW, Marlow LA, von Roemeling CA, Cooper SJ, Kreinest P, et al. (2010) Pathway signature and cellular differentiation in clear cell renal cell carcinoma. PLoS One 5: e10696.
44. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, et al. (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 102: 15545-15550.
45. Mootha V, Lindgren C, Eriksson K, Subramanian A, Sihag S, et al. (2003) PGC-1 -responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nature genetics 34: 267-273.
46. Papadopoulos GL, Reczko M, Simossis VA, Sethupathy P, Hatzigeorgiou AG (2009) The database of experimentally supported targets: a functional update of TarBase. Nucleic Acids Res 37: D155-158.
47. Xiao F, Zuo Z, Cai G, Kang S, Gao X, et al. (2009) miRecords: an integrated resource for microRNA-target interactions. Nucleic Acids Res 37: D105-110.
48. Betel D, Wilson M, Gabow A, Marks DS, Sander C (2008) The microRNA.org resource: targets and expression. Nucleic Acids Res 36: D149-153.
49. Hsu SD, Chu CH, Tsou AP, Chen SJ, Chen HC, et al. (2008) miRNAMap 2.0: genomic maps of microRNAs in metazoan genomes. Nucleic Acids Res 36: D165-169.
50. Gardner H, Ha S, Reynolds C, Chodosh L (2000) The caM kinase, Pnck, is spatially and temporally regulated during murine mammary gland development and may identify an epithelial cell subtype involved in breast cancer. Cancer research 60: 5571-5577.
51. Deb TB, Coticchia CM, Barndt R, Zuo H, Dickson RB, et al. (2008) Pregnancyupregulated nonubiquitous calmodulin kinase induces ligand-independent EGFR degradation. Am J Physiol Cell Physiol 295: C365-377.
52. Coulouarn C, Factor VM, Andersen JB, Durkin ME, Thorgeirsson SS (2009) Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene 28: 3526-3536.
53. Tsai W, Hsu P, Lai T, Chau G, Lin C, et al. (2009) MicroRNA 122, a tumor suppressor microRNA that regulates intrahepatic metastasis of hepatocellular carcinoma. Hepatology 49: 1571-1582.
54. Ruan K, Song G, Ouyang G (2009) Role of hypoxia in the hallmarks of human cancer. J Cell Biochem 107: 1053-1062.
55. Beroukhim R, Brunet JP, Di Napoli A, Mertz KD, Seeley A, et al. (2009) Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney. Cancer Res 69: 4674-4681.
56. Manalo DJ, Rowan A, Lavoie T, Natarajan L, Kelly BD, et al. (2005) Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1. Blood 105: 659-669.
57. Semenza GL (1999) Regulation of mammalian O2 homeostasis by hypoxiainducible factor 1. Annu Rev Cell Dev Biol 15: 551-578.
58. Vogelstein B, Kinzler KW (2004) Cancer genes and the pathways they control. Nat Med 10: 789-799.
59. Juan D, Alexe G, Antes T, Liu H, Madabhushi A, et al. (2009) Identification of a microRNA panel for clear-cell kidney cancer. Urology. 75: 835-841.
60. Seitz H, Youngson N, Lin SP, Dalbert S, Paulsen M, et al. (2003) Imprinted microRNA genes transcribed antisense to a reciprocally imprinted retrotransposon- like gene. Nat Genet 34: 261-262.
61. Lau NC, Lim LP, Weinstein EG, Bartel DP (2001) An abundant class of tiny RNAs with probable regulatory roles in Caenorhabditis elegans. Science 294: 858-862.
62. Lee Y, Jeon K, Lee JT, Kim S, Kim VN (2002) MicroRNA maturation: stepwise processing and subcellular localization. EMBO J 21: 4663-4670.
63. Sutherland GR (1979) Heritable fragile sites on human chromosomes. III. Detection of fra(X)(q27) in males with X-linked mental retardation and in their female relatives. Hum Genet 53: 23-27.
64. Weng L, Wu X, Gao H, Mu B, Li X, et al. (2010) MicroRNA profiling of clear cell renal cell carcinoma by whole-genome small RNA deep sequencing of paired frozen and formalin-fixed, paraffin-embedded tissue specimens. J Pathol 222: 41-51.
65. Hegedus Z, Zakrzewska A, Agoston VC, Ordas A, Racz P, et al. (2009) Deep sequencing of the zebrafish transcriptome response to mycobacterium infection. Mol Immunol 46: 2918-2930.
66. Li R, Yu C, Li Y, Lam TW, Yiu SM, et al. (2009) SOAP2: an improved ultrafast tool for short read alignment. Bioinformatics 25: 1966-1967.
67. Audic S, Claverie JM (1997) The significance of digital gene expression profiles. Genome Res 7: 986-995.
68. Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. Journal of the Royal Statistical Society Series B (Methodological) 57: 289-300.